LifeSci Advisors' Board Placement Initiative Announces Eighth Board Placement
13.6.2017 14:30 | NASDAQ OMX
NEW YORK, June 13, 2017 (GLOBE NEWSWIRE) -- LifeSci Advisors, a leading life sciences-focused investor relations consultancy, announced today the eighth placement of a female executive to a life sciences company board as part of their Board Placement Initiative (BPI). LifeSci Advisors launched BPI last year with the goal of connecting female executives in the life sciences industry with companies looking for board candidates. The company is pleased to share that Patricia S. Andrews, CEO of Boston Biomedical, has joined the Board of Directors of GlycoMimetics, Inc., a clinical-stage biotechnology company focused on cancer and sickle cell disease. Ms. Andrews' placement marks the eighth successful connection made by the program in less than a year, with LifeSci Advisors looking to match more candidates in the coming months.
"I'm honored to serve on the Board of Directors of GlycoMimetics, which has impressed me with its management team and very promising pipeline of treatments targeting some of today's most serious medical challenges in oncology," said Ms. Andrews. "I believe these clinical assets have potential in areas of high unmet need and should be quickly advanced towards commercialization. I would like to thank LifeSci Advisors for facilitating this introduction."
Ms. Andrews was appointed to the role of Chief Executive Officer of Boston Biomedical in April of this year. Since joining the company in 2013, Ms. Andrews has been a key driving force leading all aspects of commercial operations and medical affairs. Before joining Boston Biomedical, Ms. Andrews served as Executive Vice President and Chief Commercial Officer at Incyte, a U.S.-based biopharmaceutical company, where she led the transition from a clinical-stage research and development organization to a successful commercial enterprise, with the launch of its first-in-class, first-in-disease orphan oncology product, Jakafi®. Prior to Incyte, Ms. Andrews spent 17 years at Pfizer, culminating in her role as Vice President and General Manager of the U.S. Oncology Business Unit, a $900 million portfolio of products in colorectal cancer, breast cancer and renal cell carcinoma. Ms. Andrews received her MBA from the University of Michigan and a BA from Brown University.
"Pat has an incredible depth of experience as an operational leader and as a commercial development expert in the oncology treatment space," said Michael Rice, Founding Partner, LifeSci Advisors. "The GlycoMimetics Board of Directors will benefit greatly from her insight and expertise, and we are thrilled that LifeSci Advisors' Board Placement Initiative has been able to play a role in facilitating this appointment. It is our hope that our Board Placement Initiative will continue to support women in our industry and make the life sciences industry a more diverse and inclusive space."
"It's an asset to our Board and GlycoMimetics as a whole to be able to leverage Pat's commercial experience in oncology," said Rachel King, CEO of GlycoMimetics. "Her track record of leadership in transitioning other companies to the commercial stage will be particularly helpful to us as we continue to advance our pipeline. I'd like to thank LifeSci Advisors for its Board Placement Initiative, which assisted in helping to identify several outstanding candidates, including Pat."
LifeSci Advisors' Board Placement Initiative is accepting resumes from interested candidates and referrals on an ongoing basis. Resumes or open board seat positions can be sent to firstname.lastname@example.org. You can find out more information about BPI and LifeSci Advisors' commitment to board diversity by visiting www.lifesciadvisors.com/board-diversity-initiatives.
About LifeSci Advisors, LLC:
LifeSci Advisors, LLC (www.lifesciadvisors.com) is a unique investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. With a local presence in New York, Boston, Chicago, Philadelphia, London, Geneva and Tel Aviv, the firm provides the highest quality service for its clients through its deep sector specialization. Our roster of PhDs enables us to better understand our clients' R&D, regulatory, and commercial strategy, and our team of capital markets, investor relations, and public relations specialists help our clients effectively communicate to the marketplace. This combination of life sciences, capital markets, and investor relations competencies allows us to provide a valuable and highly differentiated service offering to our clients.
About LifeSci Partners:
LifeSci Partners (www.lifescipartners.com) is the leading provider of comprehensive consulting services in the areas of investor relations, corporate communications, public relations and capital markets advisory. Combining deep domain expertise in the life sciences and decades of experience in capital markets and public relations, we deliver unparalleled services to life sciences companies globally. LifeSci Partners has a physical presence in New York, Boston, Chicago, Philadelphia, London, Geneva and Tel Aviv.
For further information, please contact: Michael Rice Founding Partner LifeSci Advisors, LLC (646) 597-6979 email@example.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LifeSci Advisors, LLC via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste nyheterna från NASDAQ OMX
Nasdaq Closing Cross Calculates Russell US Indexes Reconstitution for the 14th Consecutive Year24.6.2017 01:52 | Pressmeddelande
A new record $28.9 billion traded at the closing cross in a Russell reconstitution NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- Nasdaq (Symbol: NDAQ) today announced the Nasdaq Closing Cross was used for the 14th consecutive year to rebalance Nasdaq-listed securities in the entire family of Russell US Indexes, part of leading global index provider FTSE Russell, during its annual reconstitution. More than 972 million shares representing a record $28.9 billion were executed in the Nasdaq Closing Cross in 0.861 seconds across some 2,499 Nasdaq-listed stocks. The previous record for dollars traded at the closing cross in a Russell reconstitution was $21.1 billion in 2015. "For the 14th consecutive year of partnering with FTSE Russell on the rebalance, we witnessed the advanced capabilities and market integrity of Nasdaq's INET technology platform resulting in transparent and efficient price discovery which benefits issuers and investors alike,"
LifeSci Advisors' Board Placement Initiative Announces Ninth Board Placement23.6.2017 17:52 | Pressmeddelande
NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- LifeSci Advisors, a leading life sciences-focused investor relations consultancy, announced today the ninth placement of a female executive to a life sciences company board as part of their Board Placement Initiative (BPI), a program launched a year ago with the goal to connect female executives in the life sciences industry with companies looking for board candidates. LifeSci is pleased to share news of the appointment of Jean M. Franchi to the Board of Directors of Biophytis, a biotech company listed on Euronext Paris (ALBPS) focused on drugs that target diseases of aging, with drug candidates in clinical development for dry AMD and Sarcopenia. "I'm honored to join the Biophytis board, and look forward to helping the company achieve a more global presence as it advances its portfolio of innovative therapies addressing unmet needs associated with aging," said Ms. Franchi. "I want to extend my kind thanks to LifeSci
Fentress Architects Announces its Annual Student Global Challenge23.6.2017 09:00 | Pressmeddelande
6th edition invites students to re-envision the terminal building in the year 2075 Denver, Colorado, June 23, 2017 (GLOBE NEWSWIRE) -- Fentress Architects, based in Denver, Colorado, announces the 2017 Fentress Global Challenge, an international design competition for young and student architects. As in years past, the theme, consistent with the firm's expertise in airport design and aviation, is envisioning an airport of the future. Participants are encouraged to re-envision the terminal building in the year 2075 using one of 10 existing international airports, taking into consideration local context, technological trends, and project feasibility and passenger experience. This is the sixth year that Fentress Architects has sponsored and administered the award, which brings a First Prize of $15,000 and a summer internship at Fentress' Denver office; four additional winners will receive smaller cash awards.
Oxford Immunotec Announces National Reimbursement for the T-SPOT®.TB Test in France22.6.2017 22:50 | Pressmeddelande
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a decision from the French Ministry of Health and Social Affairs to reimburse interferon gamma release assays, or IGRAs, for latent TB screening in at risk patient populations. Upon implementation of the new reimbursement codes, which is expected in the next 21 days, the French Ministry of Health and Social Affairs will provide reimbursement for the T-SPOT. TB test at a rate of approximately 60 Euros per test. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-r
Standard Lithium Raises $7.4 Million in Oversubscribed Financing22.6.2017 21:49 | Pressmeddelande
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 22, 2017 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLL) (FRA:S5L) is pleased to announce that it has completed the private placement of 9,894,785 common shares at a price of $0.75 per share for gross proceeds of $7,421,089. Interest in the placement far exceeded the expectations of the Company, and the additional amount raised provides the Company with the capital needed to advance its current projects and pursue strategic acquisitions in the lithium sector. "We are extremely pleased with the interest received in this placement, and completion represents a significant milestone for the Company," commented Anthony Alvaro, a director of the Company. "The strong demand speaks to the growing confidence in our team, projects and futur
IAGC: Plankton Study Speculative and Needs Better Data22.6.2017 16:08 | Pressmeddelande
Houston, TX, US, June 22, 2017 (GLOBE NEWSWIRE) -- The International Association of Geophysical Contractors (IAGC) released the following statement regarding the publishing of research on the interaction of seismic surveys and zooplankton in Nature: Ecology and Evolution. The IAGC President, Nikki Martin issued the following statement: "While we found the study interesting, we are also troubled by the small sample sizes, the large day-to-day variability in both the baseline and experimental data, and the large number of speculative conclusions that appear inconsistent with the data collected over a two-day period. Both statistically and methodologically, this project falls short of what would be needed to provide a convincing case for adverse effects from geophysical survey operations. "Although the initial report is peer-reviewed, it has not been widely accepted by the expert scientific community. We look forward to discussing this topic further with
I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt nyhetsrum